About Us - Kineta Inc. Kineta is a leader in developing fully human antibody drugs directed against novel innate immune targets Kineta’s focus on innate immunity differentiates it from other immuno-oncology companies that are primarily focused on adaptive immunity and T cell focused therapies
Kineta Announces Restructuring and Exploration of Strategic . . . SEATTLE, Feb 29, 2024 — Kineta, Inc (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has completed a review of its business, including the status of its programs, resources and capabilities
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to . . . TAMPA, FL and SEATTLE, WA, December 12, 2024 – TuHURA Biosciences, Inc (Nasdaq: HURA) (“TuHURA”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta, Inc (OTC Pink: KANT) (“Kineta”), a clinical-stage biotechnology company focused on the
Kineta Completes Reverse Merger with Yumanity Therapeutics Seattle, WA — (December 19, 2022) Kineta, Inc (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today the completion of its reverse merger with Yumanity Therapeutics, Inc (“Yumanity”)
Press Releases - Kineta Inc. Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1 •
Careers - Kineta Inc. Kineta, Inc is a Seattle-based biotech company with a mission to develop next-generation immunotherapies that transform patients’ lives Since the company’s inception, our focus has been targeting novel innate immune pathways where the biology had not yet translated into innovative therapies
Pipeline - Kineta Inc. Kineta is building next-generation immunotherapies to address the major challenges with current cancer treatments We aim to improve outcomes for cancer patients by solving the problems of cancer resistance Our novel drug programs are focused on addressing and correcting immuno-suppression, exhausted T-cells and poor tumor immunogenicity
Overview - Kineta Inc. Kineta is a leader in developing fully human antibody drugs directed against novel innate immune targets Kineta’s focus on innate immunity differentiates it from other immuno-oncology companies that are primarily focused on adaptive immunity and T cell focused therapies